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In longitudinal
Q1
studies of biomarkers, an outcome of interest is the time at which a biomarker reaches a particular threshold.
The CD4 count is a widely used marker of human immunodeficiency virus progression. Because of the inherent variability of
this marker, a single CD4 count below a relevant threshold should be interpreted with caution. Several studies have applied
persistence criteria, designating the outcome as the time to the occurrence of two consecutive measurements less than the
threshold. In this paper, we propose a method to estimate the time to attainment of two consecutive CD4 counts less than
a meaningful threshold, which takes into account the patient-specific trajectory and measurement error. An expression for
the expected time to threshold is presented, which is a function of the fixed effects, random effects and residual variance.
We present an application to human immunodeficiency virus-positive individuals from a seroprevalent cohort in Durban,
South Africa. Two thresholds are examined, and 95% bootstrap confidence intervals are presented for the estimated time to
threshold. Sensitivity analysis revealed that results are robust to truncation of the series and variation in the number of visits
considered formost patients. Caution shouldbe exercisedwhen interpreting the estimated times for patientswhoexhibit very
slow rates of decline and patients who have less than threemeasurements. We also discuss the relevance of themethodology
to the study of other diseases and present such applications. We demonstrate that the method proposed is computationally
efficient and offers more flexibility than existing frameworks. Copyright © 2016 JohnWiley & Sons, Ltd.
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1. INTRODUCTION
Biomarkers are widely used in the screening, diagnosis andmoni-
toring of several diseases. In screening programmes, cohort stud-
ies and clinical trials where interest lies in a repeatedly measured
biomarker, the outcome of interest may be the time at which a
biomarker reaches a particular threshold. Biomarkers for clinical
events are particularly useful in the study of the human immun-
odeficiency virus (HIV) progression due to the long natural history
of the disease. CD4 cells, which are lymphocyte cells responsi-
ble for immune response to infections, are the primary target
of the virus and are cited as a relevant predictor of acquired
immunodeficiency syndrome (AIDS) related illness and death [1].
A comprehensive review of CD4 count as a surrogate marker for
AIDS defining illnesses and death can be found in [2]. Another rel-
evant biomarker is viral load (VL), which quantifies the level of HIV
in blood. VL is used as a surrogate marker for treatment efficacy,
AIDS-defining illnesses and death [3]. TheWorld Health Organiza-
tion (WHO) guidelines recommend treatment for all HIV-positive
patients, but emphasize treatment as a priority for patients with
CD4 counts less than 350 cells/mm3 or WHO stage 3 or 4 symp-
toms [4]. Hence, in the absence of clinical manifestations, the
urgency of treatment initiation is based on a single CD4 count
measurement less than 350 cells/mm3. The time to reach a rele-
vant CD4 count threshold is also used as an endpoint in HIV/AIDS
clinical trials as a marker of treatment success and in cohort
studies where interest is in examining HIV progression.
A study of variability of CD4 count in patients enrolled in
the ACTG trial revealed that measurements taken 8 weeks apart
differed by 20% [5]. [6] and [7] attribute this variability in CD4
counts to several factors including diurnal variation, measure-
ment error, psychological and physical stress, diet and the men-
strual cycle. Owing to the inherent variability of this marker, a
single CD4 count below a relevant threshold should be inter-
preted with caution.
1.1. Current approaches to time to thresholdmodelling
1.1.1. Standard approaches. The time to CD4 threshold has been
analysed as an outcome in several recent studies. The convention
in such studies is to first extract the time of the event, which is
analysed in a second stagewithin the survival analysis framework.
[8] analysed the time to first CD4 count less than 350 cells/mm3
as the primary outcome in their study, which compared the rate
of HIV progression pre and post the introduction of antiretroviral
therapy (ART). In a recent application, [9] examined the effect of
the rs12252-C genotype on HIV progression, which was defined
aBiostatistics Unit, Medical Research Council, Durban, South Africa
bI-BioStat, Universiteit Hasselt, Diepenbeek, Belgium
cI-BioStat, KU Leuven, Leuven, Belgium
*Correspondence to: Tarylee Reddy, Biostatistics Unit, Medical Research Council,
Durban, South Africa.
E-mail: tarylee.reddy@mrc.ac.za
Pharmaceut. Statist. 2016 Copyright © 2016 John Wiley & Sons, Ltd.
1
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
UN
CO
RR
EC
TE
D
PR
OO
F
T. Reddy et al.
as the time of the first CD4 count less than 350 cells/mm3. [10]
studied a cohort of recently infected individuals where the effect
of HIV subtype on HIV progression was examined. In this study,
immunologic progression was defined as time from seroconver-
sion to the first of two consecutive CD4 cell counts less than or
equal to 350 cells/mm3. Imposing persistence criteria such as a
‘two consecutive’ rule is an improvement on basing clinical deci-
sions on a single CD4 count, but can be unreliable when the time
between visits is large. In addition, patients who enter the study
with a CD4 count already below the relevant threshold, typically
are excluded in modelling time to threshold. Removing these
patients from the analysis results in left truncation and biased
inferences.
1.1.2. General model-based approaches. A criticism of the stan-
dard approach discussed earlier is that it ignores the inherent
subject-specific CD4 count trajectory and assumes that the event
times are observedwithout error. Model-based approaches to the
time to threshold of a biomarker have recently emerged. One
such approach is inverse estimation or calibration. [11] exam-
ined the time for subjects enrolled in the ’Multicentre aneurysm
screening study’ to reach an aneurysm diameter of 55 mm. The
researchers used the method of inverse estimation in linear and
quadratic subject-specific curves from a Bayesian hierarchical
model. The estimated times to threshold were found to be too
imprecise to be used in practice. In cases where the interest lies
in modelling the time to threshold of an ordinal variable, contin-
uous time Markov models have proven to be useful. This involves
forming a distinct set of states and computing the mean first
hitting time to a particular state. [12] added to this methodol-
ogy by studying the first hitting time to a state followed by a
fixed duration of stay in the state. This was applied to a study
on multiple sclerosis where sustained progression based on a
disability scale was of interest. When the outcome of interest
is a continuous biomarker, the construction of discrete states is
somewhat arbitrary. Furthermore, due to the high degree of vari-
ability of the biomarker, reverse transitions and transitions that
skip intermediate states are often observed [13].
1.1.3. Contribution and organization of this paper. In this paper, we
propose an approach to time to thresholdmodelling that involves
two stages. In the first stage, a linear mixed model is fitted to
the longitudinal measurements, resulting in patient-specific pre-
dicted values that are a function of the fixed effects and empirical
Bayes estimates. In the second stage, the probability of experienc-
ing two consecutive measurements less than a relevant thresh-
old k at each time point is computed and substituted into the
expression for the expected time to threshold. The methodology
underlying our proposed method is presented in Section 2 and
the Appendix. This approach, which was motivated by time to
threshold modelling in the HIV setting, is applied in Section 3 to
data emanating from a cohort of HIV-positive individuals in South
Africa. For ease of presentation, we draw attention to the esti-
mated time to threshold for four selected patients, each of whom
exhibits a different CD4 count evolution. We assess the sensitivity
of results to changes in the time points considered and present
these results in Section 3.4. In addition to the HIV application, in
Section 4, we discuss the relevance of the methodology to the
study of other diseases and present three specific applications.
In Section 5, we discuss the performance and flexibility of our
proposed approach and present areas of further work.
2. METHODOLOGY
2.1. Expected time to attain threshold
We propose a method to estimate the time to attain two consec-
utive CD4 counts less than or equal to the relevant threshold k.
For readability, we will refer to the attainment of two consecutive
CD4 counts less than the threshold, as the event of interest. In the
approach we propose, we consider the individual ‘at risk’ for the
event both prior to and post enrolment. Letting Yij denote the
CD4 count observed on individual i at time point j, where j D 1
corresponds to an occasion at which one starts considering the
individual as possibly seroconverting, the time to event Ti can be
expressed as
Ti D minf j  2 : Yij1  k, Yij  kg. (1)
It follows that the expected time for individual i to attain two con-
secutive CD4 counts less than the threshold k can be expressed as
follows:
E.Ti/ D ti2P.Yi1  k, Yi2  k/ C ti3P.Yi1 > k, Yi2  k, Yi3  k/
C ti4 fP.Yi1 > k, Yi2 > k, Yi3  k, Yi4  k/
C P.Yi1  k, Yi2 > k, Yi3  k, Yi4  k/g
C : : :
D
1X
jD2
tijSij ,
(2)
where tij represents the time corresponding to the jth visit for
individual i, and Sij denotes the probability of individual i experi-
encing the event, or ‘stopping’, at tij . In practice, the infinite series
may be truncated at a time point considered relevant to the spe-
cific application at hand. Possible options for the time at which
the series is truncated are the expected lifetime of an individual,
or the end of the incubation period of a particular disease. We
specify a linear mixed model, which satisfies
yi D Xiˇ C Zibi C "i ,
bi  N.0,D/,
"i  N.0,†i/,
(3)
where b1, : : : ,bN,"i , : : : ,"N are independent. ˇ and bi represent
the fixed and random effects, respectively [14]. It follows that
yijbi  N.Xiˇ C Zibi ,†i/.
As presented in (2), Sij is the sum of several joint probabilities,
each of which represents a distinct combination of the values of
Yij that may yield the event at time point j. Assuming conditional
independence in (3) such that †i D 2Ini , the joint probabilities
that form Sij reduce to the product of the individual probabilities.
Hence, Sij may be simplified as follows:
Sij.Xi , Zi ,bi ,ˇ/ D Cij3P.Yij2 > k/P.Yij1  k/P.Yij  k/
D Cij3Œ1  Qˆ ij2.k/Œ Qˆ ij1.k/Œ Qˆ ij.k/,2
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where Cij3 denotes the ‘continuation probability’ at time
tij3 and Qˆ ij.k/ is a cumulative normal distribution with mean
x 0ijˇ C z0ijbi and variance 2. It follows that Qˆ ij.k/ can be
expressed as a simple function of the standard univariate normal
distribution:
Qˆ ij.k/ D ˆ
 
k  x 0ijˇ  z0ijbi

!
. (4)
Therefore, the estimated individual probability Qˆ ij.k/ is a func-
tion of the fixed effects estimates, empirical Bayes estimates and
measurement error. For a model with a strictly decreasing trend
in tij , at a fixed threshold k, one would expect the probability in
(4) to decrease with increasing j. The assumption of conditional
independence in (3) and the recursive relationship of continua-
tion probabilities simplify the computation of E.Ti/, but may be
extended to accommodate correlated residuals. Admittedly,more
complex multivariate normal probability manipulation will then
be necessary.
The continuation probability Cij can also be interpreted in the
survival analysis framework as the probability of individual i being
at risk for the event after time tij . That is, the probability that indi-
vidual i has not experienced two consecutive low CD4 counts at,
or prior to time point j. It should be evident that as j increases
the computation of Cij will become increasingly complex due
to the number of combinations considered. Careful examina-
tion of the pattern governing the number of combinations that
result in continuation at each time point revealed the recursive
relationship
Cij D Cj2Œ1  ˆij1.k/Œˆij.k/ C Cj1Œ1  ˆij.k/. (5)
Further details regarding the proof of (5) and its computation can
be found in the Appendix.
2.2. Estimation and inference
It follows from Section 2.1 that E.Ti/ is a function of the parame-
tersˇ , bi and  . HencebTi , the estimate of E.Ti/, can be computed
by substituting each unknown parameter by its corresponding
estimate. Further details on inference for fixed effects and empiri-
cal Bayes prediction of the random effects in a linearmixedmodel
can be found in [14]. In principle, the Delta method may be used
to compute standard errors and 95% confidence intervals for bTi .
However, the bootstrap offers a more feasible alternative. We pro-
pose a conditional version of the non-parametric bootstrap to
compute 95% confidence intervals forbTi as follows:
Step 1. Individual i is removed from the full dataset resulting
in N  1 cases
Step 2. Sample N  1 subjects with replacement from the
dataset in step 1
Step 3. Append the data of individual i to the bootstrap
sample
Step 4. ComputebTi
This process is repeated 1000 times.
3. APPLICATION: REPEATED CD4 COUNT
MEASUREMENTS FROMA COHORT OF
HUMAN IMMUNODEFICIENCY
VIRUS-INFECTED INDIVIDUALS
3.1. Study population
The Sinikithemba cohort comprises 450 HIV-1 subtype C chron-
ically infected adults enrolled at the McCord Hospital (Durban,
South Africa) between August 2003 and 2008. Sociodemographic
characteristics, plasma VL and CD4 count measurements were
obtained at baseline. The CD4 count and VL were measured
every 3 and 6 months, respectively, from enrolment. VLs were
determined using the automated CobasAmplicor HIV-1 Monitor
test (version 1.5; Roche Diagnostics). CD4 cells were enumer-
ated using the Multitest kit (CD4/CD3/CD8/CD45) on a FACSCal-
ibur flow cytometer (Becton Dickinson). In accordance with the
National HIV Treatment Guidelines implemented during the study
period, patients were recommended to start ART upon reaching a
CD4 count less than 200 cells/mm3 orWHO stage 3 or 4 symptoms
[15]. For the purposes of this particular application, 114 patients
who had not returned for a subsequent CD4 count measurement
after enrolment or who were not confirmed ARV-naive at study
entry were excluded from the analysis, resulting in a cohort of 336
patients. Themedian CD4 count at enrolment was 357 (interquar-
tile range: 259–509) cells/mm3 and the mean VL was 4.7 log
copies/ml. The overall mean age at enrolment was 33 years and
80% of the patients were women.
3.1.1. Follow-up and censoring. Patients were followed up for a
median of 2.48 years (interquartile range: 0.61–4.78 years) and
had a median of 8 CD4 count measurements (interquartile range:
3–17 visits). A total of 136 (40%) patients were removed from the
study at varying times due to initiation of ART, six of whom were
pregnant women. The study ended in 2011, and the follow-up
of 124 patients who were still under observation and had not
yet initiated ART was terminated. There were 76 (23%) patients
who dropped out of the study prematurely. Individuals whose
CD4 count measurements were terminated because of study end
can be considered to exhibit a dropout pattern that is com-
pletely at random [16]. Because ART was recommended at the
time of first CD4 count less than 200 cells/mm3, the reason for
removal from the study for these patients can be considered to
be at random given that it was based on the observed measure-
ments. The reasons for dropout in the 76 patients was unknown
except for five patients who declared relocation as their reason for
leaving the study. In this paper, we assume ignorability and con-
duct likelihood-based analysis. We comment further on explicit
modelling of the dropout mechanism in the discussion.
3.1.2. Additional assumptions. Because this is a seroprevalent
cohort, the date of the last negative HIV test result is unknown,
and hence, the date of seroconversion cannot be estimated with-
out the analysis of additional patients with known dates of infec-
tion. For this particular analysis, we have examined two possible
timescales: date of first contact as time zero and time on study,
which is expressed as the difference between the enrolment date
and the date at which the study commenced (1 August 2003).
As stated by [11], different timescales in hierarchical models can
have a strong impact on the predicted random effects due to the
shrinkage effect. We allow a 10-year window prior to enrolment
where we consider an individual as having the potential to have
experienced the threshold. The rationale for this decision is based
on the estimated time from seroconversion to death in ART-naive
patients, which was reported to be approximately 10 years in
sub-Saharan Africa [17,18].
3.2. Linear mixedmodel
A variance stabilizing square root transformation was applied to
the CD4 count responses. The observed CD4 count trajectories for
Pharmaceut. Statist. 2016 Copyright © 2016 John Wiley & Sons, Ltd.
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eight selected patients is presented in Figure 1. This figure clearlyF1
depicts the high degree of between and within individual vari-
ability. To explore the relationship between baseline VL and rate
of CD4 decline, baseline VL was categorized into approximate ter-
tiles as follows: VL  15 000, 15 000 < VL  100 000 and
VL > 100 000 log copies/ml, which represent low, intermediate
and high VL, respectively.
There were 92 (27%), 117 (35%) and 127 (38%) patients in
the low, intermediate and high VL categories, respectively. We
applied the ‘general guidelines formodel building’ recommended
in [14], commencing with an elaborate mean structure, which
included age, gender, baseline VL and interaction terms as covari-
ates. Although the subject-specific plots and reduced AIC indi-
cated that a quadratic or cubic model may provide a better fit
to the observed data than the linear model, these models would
result in implausible predicted trajectories outside of the obser-
vation period. By comparing nested models using the likelihood
ratio test, the inclusion of age and gender did not significantly
Figure 1. Longitudinal CD4 count measurements for eight subjects on the square
root scale.
improve the model fit (p D 0.150). The reduced model was of the
form:
Yij D
8<:
ˇ0,L C b0iCˇ1,Ltij C b1itij C "ij if ‘low’ viral load,
ˇ0,MCb0iCˇ1,MtijCb1itijC"ij if ‘intermediate’ viral load,
ˇ0,H C b0iC ˇ1,HtijC b1itij C "ij if ‘high’ viral load.
The restrictedmaximum likelihood estimateswith standard errors Q2
for each of the timescales are presented in Table I. T1
As expected, the model with the time origin as 1 August 2003
resulted in a higher variance of the random intercepts. Through
comparison of the AIC and BIC for the two models it is clear that
the model with time since enrolment as the timescale provided a
better fit to the data. All further analysis was therefore conducted
in this timescale, which also facilitates interpretation of the esti-
mated times as times relative to enrolment in the study. We found
an overall significant difference in intercepts and slopes between
VL categories (p < 0.0001 and 0.0053, respectively). Patients with
high VL displayed a significantly higher rate of decline in CD4
count than patients with low VL (p < 0.0001). More rapid decline
in patients with high VL compared with intermediate VL was
observed; this result was not statistically significant (p D 0.115).
3.3. Expected time to threshold
As stated in Section 2, we consider an individual to be at risk
of obtaining two consecutive values lower than the threshold k
up to a maximum of 10 years prior to and post enrolment. The
discrete times that fall outside of the observation periodwere cre-
ated in accordance with the study design of three monthly visits.
The series was truncated at the visit at which the predicted CD4
count bYij dropped to zero. Similarly, time ti1 was defined as the
minimum time at which bYij < 1500 cells/mm3, which is the upper
limit of the CD4 count range for HIV infected individuals. We esti-
mated the time to obtain two consecutive measurements less
than the threshold values 200 and 350 cells/mm3, respectively.
For ease of presentation, we have chosen to draw attention to
the estimation for four specific patients (Figure 2). The estimated F2
Table I. HIV cohort data. Parameter estimates (standard errors) for the fitted
models on each timescale.
Effect Parameter Time-enrolment Time-calendar origin
Fixed effects estimates (s.e.)
Intercept ˇ0,L 21.2405 (0.4708) 22.0000 (0.5513)
ˇ0,M 19.4469 (0.4190) 20.6554 (0.4978)
ˇ0,H 16.2821 (0.4057) 17.5021 (0.4909)
Time ˇ1,L 0.5744 (0.1206) 0.5658 (0.1171)
ˇ1,M 1.0160 (0.1137) 0.9454 (0.1102)
ˇ1,H 1.3839 (0.1400) 1.1066 (0.1331)
Covariance parameter estimates (s.e.)
var.b0i/ d11 19.5555 (1.6080) 25.5456(2.2716)
cov.b0i , b1i) d12 0.4944 (0.3821) 2.1611 (0.4703)
var.b1i/ d22 0.9941 (0.1421) 0.9438 (0.1303)
Measurement error 2 3.1923 (0.0810) 3.2135 (0.0814)
Fit statistics
AIC 17185.3 17225.9
BIC 17200.5 17241.1
2 REML log-likelihood 17177.3 17217.9
REML, restricted maximum likelihood.4
Copyright © 2016 John Wiley & Sons, Ltd. Pharmaceut. Statist. 2016
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Figure 2. Longitudinal CD4 count measurements with reference at thresholds 200
and 350 cells/mm3.
probabilities of a single measurement being below the threshold
was computed using the estimates from the linear mixed model
presented in Section 3.2 and expression (4), whichwas introduced
in Section 2.
Patient A entered the study with a CD4 count substantially
above the 200 and 350 cells/mm3 thresholds and declined at a
very slow rate. This is captured by the fitted probabilities where
the probability of patient A obtaining a CD4 count less than
200 cells/mm3 is zero throughout the period considered. The
probability of patient A experiencing a CD4 count less than 350
cells/mm3 increases at 5 years. The estimated time to two con-
secutive measurements less than the 200 and 350 cells/mm3
threshold is presented in Table II.T2
Patient B, who entered the study with a CD4 count above the
350 cells/mm3 threshold, exhibited a more rapid rate of CD4
count decline than patient A. The estimated time for patient B to
reach a threshold of 350 and 200 cells/mm3 was 2.3 and 4.3 years,
respectively. Patients C and D both entered the study with CD4
counts less than 350 but declined at different rates. This is cap-
tured by the predicted probabilities in Figure 3. Patient C wasF3
estimated to have reached the 200 cells/mm3 threshold 0.38 years
post enrolment, and the 350 threshold 3.26 years prior to enrol-
ment. The confidence intervals for the estimated times for patient
C reveal that poorer precision is obtainedwhen analysing individ-
uals with few measurements. Caution should be exercised when
interpreting the estimated times for patients who start at a high
CD4 count and exhibit a very slow rate of decline. Probabilities
of low CD4 count that are zero throughout the period of obser-
vation do not pose a problem, but probabilities that increase to
greater than zero later in the period can result in estimated times,
which are sensitive to the frequency and timing of unobserved
measurements which are considered. This is discussed further in
Section 3.4.
Several possible analyses using the estimated times can be
conducted. We have elected to focus on the estimated proba-
bilities and times themselves as they draw attention to several
current issues in the treatment and monitoring of HIV-positive
patients. There were 30 individuals who had a zero probability of
obtaining a single CD4 count less than 200 cells/mm3 through-
out the period considered. These individuals are referred to as
long-term non-progressors. This contributes additional evidence
to the proposition that there are individuals who, possibly due to
genetics, are able to control the virus. In addition, the estimated
times draw attention to a serious public health concern, namely,
late presentation for HIV testing. Excluding the individuals who
were long-term non-progressors, the percentiles of the estimated
times were computed. Fifteen per cent of these patients had
already attained a CD4 count less than 200 cells/mm3 more
than 6 months prior to first presentation at the clinic. Hence,
patients were choosing to have an HIV test when they were
already in the advanced stages of HIV. The ARV treatment guide-
line in effect during the study recommended treatment initiation
at a CD4 count less than 200 cells/mm3. Therefore, an addi-
tional interpretation is that 15% of the patients deviated from
the recommended timing of treatment initiation by more than
6 months. After 2011, the treatment initiation cutoff was raised
to 350 cells/mm3. During our study period, we found that 35%
of patients had already attained two consecutive CD4 counts less
than 350 cells/mm3 more than 2 years prior to enrolment. It is
clear that, unless patients present at the clinic earlier for test-
ing, changing treatment guidelines may not have the desired
effect. It would be interesting to examine whether health seeking
behaviour has changed over time, by studying individuals who
first presented at the clinic after 2011.
3.4. Sensitivity to variation in observation frequency
In Section 3.3, we considered an individual to be at risk of expe-
riencing a CD4 count below the thresholds of interest, 10 years
prior to andpost enrolment, and generated regular threemonthly
visits for the unobserved period. In this section, we assess the
sensitivity of the estimated time to threshold to truncation and
the regularity and frequency of visits by simulation. The following
scenarios were considered:
Scenario 1. A period of 10 years prior to and post enrolment
was considered, and visits outside the observed period
occurred at regular three monthly intervals.
Table II. Estimated time to threshold for patients A, B, C and D.
 200 cells/mm3  350 cells/mm3
Patient VL Baseline CD4 bTi 95% CI bTi 95% CI
A Low 783 2.92  105 (8.88  106, 8.24  105) 3.1552 (2.4946, 3.7362)
B Low 478 4.2858 (4.2343, 4.3843) 2.3046 (2.2887, 2.3169)
C High 204 0.3758 (0.0267, 0.5319) 3.2608 (5.0051, 2.2874)
D High 261 2.3335 (2.3005, 2.3763) 0.2043 (0.4039, 0.0642)
VL, viral load.
Pharmaceut. Statist. 2016 Copyright © 2016 John Wiley & Sons, Ltd.
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a: Probability of single CD4 count  less than 200 cells/mm3
b: Probability of single CD4 count  less than 350 cells/mm3
Figure 3. (a) Probability of single CD4 count less than 200 cells/mm3 and (b)
probability of single CD4 count less than 350 cells/mm3.
Scenario 2. A period of 5 years prior to and post enrolment
was considered. Visits outside the observed period
occurred at regular three monthly intervals.
Scenario 3. A period of 10 years prior to and post enrolment
was considered, and 10% of visits outside the observation
period occurred 1 month later than expected.
Scenario 4. A period of 10 years prior to and post enrolment
was considered, and 25% of visits outside the observation
period occurred 1 month later than expected.
Scenario 5. A period of 10 years prior to and post enrolment
was considered, and 10% of visits outside the observation
period were missed.
Scenario 6. A period of 10 years prior to and post enrolment
was considered, and 20% of visits outside the observation
period were missed.
From Table III, it is clear that the number of visits considered has T3
an impact on the estimated time to threshold for individuals who
enter the study with a high CD4 count and exhibit slow decline.
Truncation of the series at 5 years results in an estimated time to
threshold of 0.005 years, whereas truncation at 10 years results in
an estimated value of 3.155 years for patient A. Similarly, the num-
ber of visits considered outside the period of observation also has
an effect for this type of patient. This is evident from the estimate
for patient A under the assumption of 20% of visits being missed.
We found that results were far less sensitive for patients experi-
encing moderate to rapid decline in CD4 count. As expected, in
individuals who are likely to reach the threshold of interest during
the observed period, the estimated time is robust to truncation
or variation in the time points considered. In all patients studied,
results were robust to variation in the timing of visits. Hence, the
estimated time to threshold is sensitive to the number of time
points for specific patients, but not to the actual values of those
time points.
4. OTHER AREAS OF APPLICATION
The methodology presented in Section 2 was motivated by the
specific problem of estimating the time to CD4 count decline
in the presence of persistence criteria, but is not limited to this
specific application. Within the HIV context, the methodology
is also well suited to prediction of the time to HIV treatment
failure, which is defined as the time at which two consecu-
tive VL measurements greater than 400 copies/ml are observed
[19]. In settings where less sensitive VL tests are available, the
cut-off of interest is 1000 copies/ml [20,21]. More generally, the
time to reach two consecutive biomarker measurements lower
than or exceeding a threshold is also of interest in the study
of non-communicable diseases such as cancer, cardiovascular
disease and diabetes. Hence, the methodology presented in
Section 2 is well suited to several applications, some of which are
briefly discussed in the following.
4.1. Diabetes screening
The glycohemoglobin (HbA1C) test, which measures blood glu-
cose levels over time, is one of the tests which are used to
diagnose diabetes. Diabetes is diagnosed when an HbA1C level
greater than or equal to 6.5% is observed. As recommended in
[22], unless clear symptoms of diabetes exist, diagnosis should
only be confirmed when a second measurement of 6.5% or
greater is observed. Prediction of the time from screening to
diagnosis of diabetes can assist with the development of more
efficient monitoring intervals for national screening programmes.
Table III. Estimated time to two consecutive measurements less than 350 cells/mm3
under various scenarios.
Patient Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 Scenario 6
A 3.1552 0.0050 3.0734 3.1271 3.0219 2.5941
B 2.3046 2.3046 2.2926 2.2926 2.2926 2.2926
C 3.2608 3.2056 3.2056 3.2073 3.2119 2.9572
D 0.2043 0.2043 0.2030 0.2097 0.1432 0.0208
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4.2. Recurrence of prostate cancer
According to the European Association of Urology guidelines
for prostate cancer, the diagnosis of treatment failure after
radical prostatectomy is defined by two consecutive values of
prostate-specific antigen greater than 0.20 ng/ml [23]. Several
studies have examined risk factors for prostate cancer recurrence
using standard approaches, which fail to take into account the
inherent trend of prostate-specific antigen and measurement
error.
4.3. Abnormal aortic aneurysm screening
In abnormal aortic aneurysm screening studies, surgery is recom-
mended to patients when the diameter of the aneurysm exceeds
55 mm [11]. Because of the high degree of within patient vari-
ability in aortic diameter measurements [24], it is of interest to
examine the effect of applying persistence criteria in this setting.
Estimation of the expected time to threshold for each patient
would enable clinicians to identify patients who may be in need
of surgery in the near future and target interventions accordingly.
5. CONCLUDING REMARKS
In this paper, we have proposed and applied a novel approach
to estimation of the time to attain two consecutive CD4 counts
less than two relevant thresholds. This approach takes into
account the estimated patient-specific trajectories and measure-
ment error. Through identification of a recursive relationship of
the continuation probabilities at each time point, we have dis-
played that the computation of the expected times is simple, effi-
cient and can be implemented using existing software packages.
The method we have proposed can also accommodate complex
functions of time, such as quadratic or cubic terms, in contrast to
the inverse estimation framework. Additional flexibility in the def-
inition of the event can be achieved by considering the sequences
that result in a continuation or ‘stop’ under the newly defined
‘stopping’ rule. For example, if the time to the attainment of three
consecutive low CD4 counts is of interest, the stopping sequence
can be decomposed into a continuation sequence at time point
j  4 followed by an outcome sequence f0, 1, 1, 1g.
Sensitivity analysis revealed that the estimated times are sensi-
tive to the number of visits considered and the time at which the
series is truncated, for patients who exhibit a very slow decline.
For other patients, however, we found that results were less sen-
sitive to the number of visits considered and truncation. Hence,
caution should be exercised when interpreting the estimated
times for patients who exhibit very slow rates of decline. Another
strong assumption that was made for the specific application
presented was that visits prior to enrolment and post dropout
occurred at regular, equally spaced time points. In the sensitivity
analysis conducted, we found that results were robust to devia-
tion from the regular observation times for all patients. The data
we have examined is a combination of coarse data due to miss-
ing observations and augmented data through the inclusion of
random effects. [25] refer to the union of coarsening and aug-
mentation as enrichment. Hence, the prediction of the expected
time is dependent on several unverifiable assumptions regarding
the random effects structure and missing data mechanism. This
raises the importance of conducting sensitivity analysis to gauge
the impact of deviations from the assumptions made [16]. Local
influence analysis may also be undertaken to determine whether
there are specific individuals who have a large impact on the
model fit, and hence, on prediction. The primary objective of this
paper is to present and apply the proposed methodology to HIV
biomarker data. Therefore, local influence analysis and missing
data models will be conducted as further work.
To appropriately handle the issue of ‘left censored’ event times
due to the study design, we considered an individual to be at
risk of the event of CD4 count decline prior to enrolment. This
was achieved by using the date of first contact as the time ori-
gin. One may also analyse the data on the timescale of time since
seroconversion if additional data from a recently infected cohort
is available. This approach would involve imputation of the time
of infection via back calculation [26] or inverse estimation. The
proposed methodology rests on the assumption that the resid-
ual variability is pure measurement error, which may be violated
in certain settings. A simulation study that was conducted by [27]
to investigate the robustness of fixed effects estimates from a
linear mixed model to a misspecified error distribution, revealed
that inference is robust when errors are non-Gaussian or het-
eroscedastic, but may be impaired when errors are correlated. In
this latter case, the authors found that the model including a ran-
dom slope in addition to the random intercept was more robust
than the random intercept model. As discussed by [28], extend-
ing a linear mixedmodel proposed by including amore elaborate
randomeffects structure is computationally simpler to implement
and can produce practically indistinguishable fits to the data
when compared with a model that includes a serial correlation
term. In some cases, extensive knowledge of the true underlying
process which generates the data, may necessitate the inclusion
of serial correlation in the model. Although more computation-
ally intensive, it is possible to relax the assumption of conditional
independence in the methodology we have proposed. As a start-
ing point, viewing the process as a first-order Markov chain and
applying the rules of conditional probability and Bayes theorem,
we are able to express the stopping probability as the product
of conditional probabilities. Assuming dependence on the most
recently observed value, these conditional probabilities may be
expressed as a function of the bivariate and univariate cumulative
normal distribution.
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Appendix
For ease of notation, the index i is suppressed in the equations
that follow.We introduce Ej , which denotes the outcome indicator
at time point j such that
Ej D

0 if Yj > k
1 if Yj  k.
Continuation after j visits can be defined in terms of the combi-
nation of outcomes observed, such that the event of two con-
secutive low CD4 count outcomes {1, 1} has not occurred at, or
prior to the jth visit. The possible combinations, which lead to
continuation after two, three and four visits, respectively, are pre-
sented in Table A.1. There are three, five and eight combinations
of outcomes that lead to continuation after time points 2, 3 and 4,
respectively.
The number of combinations, which result in continuation after
each visit, follows a Fibonacci sequence f1, 1, 2, 3, 5, 8, 13, : : :g,
where each term is defined as the sum of its two predecessors.
Specifically, the number of outcome combinations that result in
continuation after a sequence of j visits is the j C 1th Fibonacci
number, fjC1. Continuation at visit j can be expressed as a func-
tion of continuation at visit j1 and j2. A continuation sequence
should end in either (A): {0}, which is the union of {0,0} and {1,0}
Table A.1. Possible combinations of out-
comes, which result in continuation after
two, three and four visits.
E1 E2 E3 E4
j  2
1 0
0 1
0 0
j  3
1 0 1
1 0 0
0 1 0
0 0 1
0 0 0
j  4
1 0 0 1
0 1 0 1
0 0 0 1
1 0 1 0
1 0 0 0
0 1 0 0
0 0 1 0
0 0 0 0
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or (B): {0,1}. This implies that a continuation sequence of length
j can be constructed uniquely from (A): a continuation sequence
of length j  1, followed by {0} and (B): a continuation sequence
of length j  2, followed by {0, 1}. Letting Cj denote the continua-
tion probability at visit j and assuming that the outcomes at each
visit are independent, this recursive relationship can be presented
as follows:
Cj D Cj2  P.Ej1 D 0/  P.Ej D 1/ C Cj1  P.Ej D 0/.
This relationship is illustrated in Table A.1 for j D 4. Assuming
that the process ‘stops’ when two consecutive {1, 1} outcomes are
observed for the first time, the number of combinations, which
result in a ‘stop’ at sequence of j visits, is fj2. For a ‘stop’ to be
observed at any j  3, the last three outcomes in the sequence
are confined to be of the form f0, 1, 1g. Hence, the stopping
probability Sj is
Sj D Cj3  P.Ej2 D 0/  P.Ej1 D 1/  P.Ej D 1/.
Pharmaceut. Statist. 2016 Copyright © 2016 John Wiley & Sons, Ltd.
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